What smart people are saying after the Fed held rates steady We're getting an idea of how much Anthropic stock will be available for retail investors Reed Hastings says Big Tech should get used to being hated — like Big Pharma Where to watch a free World Series live stream: Brewers vs. Rays Game 5 Oracle stock pops 10% on forecast for 35% average revenue growth through 2030 Xreal Aura is a new wired headset powered by Android XR Why Progressive, No. 4 on Best Workplaces for Women, focuses on flexibility and listening Wall Street forecasters are eyeing a streak of double-digit gains brewing for stocks Looking for yield? This could be one of the best times in recent market history to buy corporate bonds Starlink is fast becoming one of the biggest factors for passengers choosing an airline, United's CEO says

Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss

Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss

Executive Summary

In the first head-to-head trial of Ozempic versus Eli Lilly's new "King Kong" drug retatrutide, the next-generation drug led to more weight loss.

Business Context

Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss is relevant for readers tracking markets, technology, wealth creation, and global business strategy.

Investor Takeaway

The key signal is whether this development changes demand, margins, capital allocation, competitive advantage, or risk expectations.

Credit: This article is based on publicly available source data and editorial synthesis.
Source: Open original source
Tags:
billionaires economy markets technology wealth

© Iconic Billionaires